Parthenolide reduces cisplatin-induced renal damage

Area of Science:

• Nephrology
• Pharmacology
• Toxicology

Background:

• Cisplatin chemotherapy can cause significant kidney damage due to inflammatory responses.
• Reactive oxygen species (ROS) activate nuclear factor-kappaB (NF-kappaB), escalating inflammation and cisplatin's toxicity.
• NF-kappaB is a key mediator in inflammatory pathways contributing to organ damage.

Purpose of the Study:

• To investigate the protective effects of parthenolide, a selective NF-kappaB inhibitor, against cisplatin-induced nephrotoxicity.
• To evaluate parthenolide's impact on inflammatory markers and renal function in a rat model.

Main Methods:

• Ninety-four male Wistar rats were assigned to six groups, including control, parthenolide-treated, and cisplatin-treated groups.
• Parthenolide or its solvent was administered before and after cisplatin injection.
• Renal function (creatinine), inflammation (ED1 immunostaining, NF-kappaB activation via EMSA), oxidative stress (lipid peroxidation), and kidney histology were assessed.

Main Results:

• Cisplatin treatment led to elevated plasma creatinine, increased ED1 and NF-kappaB expression in kidneys, and acute tubular necrosis.
• NF-kappaB activation was confirmed by electrophoretic mobility shift assay (EMSA).
• Parthenolide administration significantly reduced these cisplatin-induced markers of renal damage and inflammation.

Conclusions:

• Parthenolide effectively mitigates cisplatin-induced renal damage in rats.
• The protective mechanism involves the inhibition of the inflammatory cascade, particularly NF-kappaB activation.
• Parthenolide shows potential as a therapeutic agent to prevent chemotherapy-induced kidney injury.